At a glance
ClinicalIndex Comparison RecordN/ACompleted· 66 enrolled
Drug / intervention
dehydroepiandrosterone (DHEA)dietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Role of Dehydroepiandrosterone in the Maintenance of Mitochondrial Quality of Cumulus Cells in Poor Ovarian Responders
In Brief
A clinical study evaluating dehydroepiandrosterone (DHEA) for Poor Responders and Dehydroepiandrosterone. Completed, enrolled 66 participants across 1 site.
Detailed Summary
To investigate whether the DHEA supplementation could improve mitochondrial quality in poor ovarian responders
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPoor Responders, Dehydroepiandrosterone
CountriesTaiwan
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
Enrollment StartSep 2017
First PostedFeb 2018
Primary CompletionDec 2019
TodayJul 2026
First PostedFeb 20, 2018
Enrollment StartSep 6, 2017
Primary CompletionDec 31, 2019
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 8.4 years ago
Interventions
dehydroepiandrosterone (DHEA)dietary
Participants take DHEA 90 mg daily for two months at least before in vitro fertilization cycles.